Q2 2024 Earnings Summary
- Agilent participates in excellent markets with multiple long-term growth drivers, such as biotherapeutics characterization, improving human health, and the quality of food, and expects its service business to grow in the high single digits over the long term as they increase their attach rate.
- Despite challenging markets, Agilent maintains its long-term growth algorithm of 5% to 7% and continues to invest in biopharma, while being the undisputed leader in applied markets like PFAS, electrification, and semiconductors, which are expected to grow significantly in the next five years.
- Agilent expects to benefit from secular growth drivers in China, with continued government investment in science and technology, and gains from the consumables and service aftermarket, helping them to return to previous growth rates in the near term as markets recover.
- Agilent is experiencing significant revenue declines across key segments, with the Life Sciences and Applied Markets Group (LSAG) revenue declining 13% globally and 8% excluding China, indicating weakness beyond just the China market.
- The company is implementing additional cost-saving measures, including headcount reductions, to mitigate the impact of lower revenue, which suggests pressure on margins and weak demand; specifically, they plan to achieve $100 million in annualized savings, primarily headcount-related.
- Visibility into future business is currently limited, as acknowledged by management, due to slower-than-expected budget releases and extended approval times from customers; despite previous guidance, demand recovery has not materialized as anticipated, raising concerns about future growth projections.
-
Pharma Instrument Demand
Q: Is the pharma instrument slowdown widespread?
A: Management confirmed the slowdown in pharma instrument demand is generally across the board among customers. They emphasized it's a macro issue, not a market share loss, and stated that objective market share data shows they are holding or even gaining in some areas. -
Long-Term Growth Outlook
Q: What's the company's long-term growth outlook?
A: Despite current challenges, management believes they participate in markets with multiple long-term growth drivers, such as biotherapeutics characterization and food quality. They are not ready to walk away from their 5% to 7% growth algorithm and expect to return to these growth rates in the near term. -
China Stimulus Impact
Q: How will China stimulus affect future sales?
A: The company views the multiyear China stimulus program as very encouraging. While they don't expect any benefit in the second half, they anticipate it will have a positive impact in 2025. Customers are currently working out funding mechanisms, and there's increased bid activity as they position for stimulus funds. -
NASD Sales Outlook
Q: What's the new sales outlook for NASD this year?
A: NASD sales are now expected to be roughly $300 million this year, down from the previous expectation of $350 million. The business mix has shifted to 75% clinical and 25% commercial, with the Inflation Reduction Act impacting price provisioning. Despite this, clinical business orders are growing about 50%. -
Cost Savings Program
Q: Is the $100 million cost savings incremental?
A: Yes, the $100 million in cost savings is incremental to the savings already built into the plan. Management expects to annualize these savings by the end of the year, primarily through headcount reductions. -
Instrument Orders and Sales Funnel
Q: Have instrument orders deteriorated or just not improved?
A: Instrument orders haven't deteriorated but lacked the expected acceleration. Orders grew, with a book-to-bill greater than 1, but the conversion from the sales funnel to revenue is prolonged. Deal closure timelines remain elevated yet stable. -
China Sales and Stimulus Delays
Q: Why did China revenue soften, and how are delays impacting sales?
A: Customers in China are postponing purchasing decisions to assess potential benefits from the new stimulus program. The company doesn't expect stimulus impact in the second half but anticipates benefits in 2025. They've reduced guidance by $70 million due to these delays. -
Exposure to CDMOs in China
Q: Did exposure to large CDMOs in China contribute to weakness?
A: While there is some exposure to CDMOs, most of the company's China business is local and isn't significantly impacted by the Bio Secure Act. Management noted that weakness is not due to this factor but is more broadly across markets. -
IRA Impact on Biopharma
Q: Is the Inflation Reduction Act affecting biopharma spending?
A: The Inflation Reduction Act is an evolving factor and has impacted the NASD business. Pharma partners are seeking larger indications due to price provisioning, leading to adjustments in their spending and program strategies. -
LSAG Performance
Q: How did LSAG perform excluding China?
A: The Life Sciences and Applied Markets Group (LSAG) declined 13% globally; excluding China, it was down 8%. -
Biopharma Growth Rates
Q: What were the biopharma growth rates this quarter?
A: Biopharma revenue was down approximately 12%, while small molecule pharma was down about 10%, leading to an overall pharma decline of 11%. Last year's tough comparisons and current market conditions contributed to this decline. -
Capital Investment in NASD
Q: Will you adjust NASD capital investments after revenue change?
A: Despite near-term headwinds, there's no change in capital investment plans for NASD. Management remains excited about the long-term prospects, with clinical business growth over 50% and continued capacity expansion. -
China Sales Postponements
Q: Are customers postponing purchases due to stimulus?
A: Yes, customers in China are delaying purchases as they try to understand the stimulus funding mechanisms. This has led to a meaningful softness extending to all markets in China. -
Visibility and Guidance
Q: Has visibility improved to prevent future guidance misses?
A: Management acknowledged that visibility remains a challenge but has taken a conservative approach in guidance, not assuming any significant market inflection in the second half. They are basing guidance on current market conditions without expecting rapid improvement. -
M&A Opportunities in Biologics
Q: Is the M&A market in biologics opening up?
A: While there may be opportunities due to changing asset pricing, management intends to remain disciplined and strategic in their M&A approach, focusing on areas where they can drive growth.